PRESS RELEASE June 8, 2018

Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination

Company to Request Hearing ENGLEWOOD CLIFFS, N.J., June 08, 2018 – Immune Pharmaceuticals, Inc. (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. (“Nasdaq”) […]

Keep Reading

PRESS RELEASE May 23, 2018

Immune Pharmaceuticals Provides a Pipeline Update

  Englewood Cliffs, NJ (May 23, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today provided an update on its pipeline. “We are pleased with the progress we have made so far this year, particularly in the […]

Keep Reading

EVENT May 15, 2018

2018 Pre-IID Pemphigus and Pemphigoid Symposium

Updated results from the BP-01 phase 2a study of bertilimumab in bullous pemphigoid are being presented at the pre-IID Pemphigus and Pemphigoid Symposium in Orlando, Florida on May 15.  The data will be featured in an oral presentation by Neil Korman, MD, PhD, Director Clinical Trials Unit and the Murdough Family Center for Psoriasis, University Hospitals […]

Keep Reading

PRESS RELEASE May 15, 2018

Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

– Results from all subjects confirm excellent safety and tolerability and a large benefit across a variety of efficacy measures despite aggressive prednisone tapering- – Positive data support Company’s plans to commence pivotal registration study in 2019 –   Englewood Cliffs, NJ (May 15, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), […]

Keep Reading

PRESS RELEASE May 7, 2018

Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.

Englewood Cliffs, NJ (May 7, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the Company’s Board of Directors (the “Board”) will no longer pursue a spin-off of its oncology-focused subsidiary, Cytovia Inc. (“Cytovia”) that […]

Keep Reading

PRESS RELEASE April 2, 2018

Immune Pharmaceuticals Announces 2017 Financial Results

– Significant progress in 2017 positions Company for a breakthrough year – Englewood Cliffs, NJ (April 2, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the year and quarter ended December 31, […]

Keep Reading

PRESS RELEASE March 12, 2018

Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

ENGLEWOOD CLIFFS, NJ–(Marketwired – March 12, 2018) – Immune Pharmaceuticals, Inc.(IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today the acceptance of an abstract for a poster presentation at the 2018 Pre-IID Pemphigus and Pemphigoid Symposium: “A New Era of Translation and […]

Keep Reading

March 8, 2018

Immune Pharmaceuticals Delists from Nasdaq Stockholm Effective March 9, 2018

Englewood Cliffs, NJ (March 8, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that effective at the close of the market on Friday, 9 March 2018, the Company’s common stock will no longer trade on the Nasdaq First […]

Keep Reading

February 27, 2018

Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

Englewood Cliffs, NJ (February 27, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ FIRST NORTH; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the […]

Keep Reading

PRESS RELEASE February 27, 2018

Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

Englewood Cliffs, NJ (February 27, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the Securities […]

Keep Reading